Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Later-Line Treatment Gaps in Esophageal Adenocarcinoma Underscore Need for Continued Therapeutic Development, Multidisciplinary Care

May 28th 2025

Nataliya Uboha, MD, PhD, underscores the crucial role of molecular profiling for guiding first-line treatment approaches in esophageal adenocarcinoma.

MAIC Analysis Reveals Long-Term PFS Benefit With Zanubrutinib Over Orelabrutinib in R/R MCL

May 28th 2025

Findings from a matching-adjusted indirect comparison showed a PFS benefit with zanubrutinib vs orelabrutinib in relapsed/refractory mantle cell lymphoma.

Dr Randall on Consensus Developed at The Annual Birmingham Orthopedic Oncology Meeting

May 27th 2025

R. Lor Randall, MD, FASCO, discusses key areas of consensus discussed at the Annual Birmingham Orthopedic Oncology Meeting.

Dr Nguyen on the Evolving Landscape of Adjuvant Therapy in Localized ccRCC

May 27th 2025

Charles B. Nguyen, MD, discusses the evolving landscape of adjuvant therapy in localized clear cell renal cell carcinoma.

Full FDA Approval Underscores the Role of Larotrectinib in NTRK Fusion+ Solid Tumors

May 27th 2025

David S. Hong, MD, discusses the full FDA approval of larotrectinib for NTRK fusion–positive solid tumors.

Dr Kahl on Persisting Unmet Needs in the Treatment of Mantle Cell Lymphoma

May 26th 2025

Brad Kahl, MD, discusses the ongoing unmet needs in the treatment of mantle cell lymphoma.

Talquetamab/Teclistamab Combo Yields Responses With Increased Infection Incidence in Triple Class–Exposed Myeloma

May 26th 2025

Talquetamab plus teclistamab produced responses with a high rate of infections in relapsed/refractory multiple myeloma.

Dr McCann on the Biologic Heterogeneity Within HER2+ Breast Cancer

May 26th 2025

Kelly E. McCann, MD, PhD, discusses the biologic heterogeneity within HER2-positive breast cancer and highlights the clinical implications of HR status in this disease subset.

Post Hoc Data Show Anemia Benefits, Reduced Transfusion Burden With Momelotinib in Myelofibrosis

May 24th 2025

Momelotinib was associated with anemia benefits and reduced transfusion burden in myelofibrosis in a post hoc analysis of 4 trials.

Inavolisib Plus Palbociclib/Fulvestrant Earns Positive CHMP Opinion for PIK3CA-Mutated, ER+/HER2– Advanced Breast Cancer

May 23rd 2025

The EMA’s CHMP has recommended the approval of inavolisib plus palbociclib/fulvestrant in PIK3CA-mutated, ER-positive advanced breast cancer.

Updated STARGLO Data Show Maintained OS Benefit With Glofitamab Plus Chemo in R/R DLBCL

May 23rd 2025

Two-year follow-up data continued to show an overall survival benefit with glofitamab plus chemotherapy in relapsed/refractory DLBCL.

Mirdametinib Earns Positive CHMP Opinion for NF1-Associated Plexiform Neurofibromas

May 23rd 2025

The EMA’s CHMP has issued a positive opinion for mirdametinib for pediatric and adult patients with NF1-associated plexiform neurofibromas.

Dr Bhat on Choosing Between Pirtobrutinib and Liso-Cel for R/R CLL Management

May 23rd 2025

Seema A. Bhat, MD, discusses disease features and patient characteristics that inform the choice between pirtobrutinib and liso-cel for CLL.

OncLive Polls Reveal Picks for Top Gastrointestinal Cancer Abstracts at ASCO 2025

May 23rd 2025

GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Treatment Trends and Ongoing Research in Pediatric Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss ongoing research in pediatric acute leukemia.

Factors to Consider in Pediatric Acute Leukemia Management

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss key factors for the management of pediatric acute leukemia.

Breaking Down Treatment Expectations With Revumenib in Pediatric KMT2A+ R/R Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss treatment expectations with revumenib in pediatric relapsed/refractory acute leukemia.

Integrating 25-mg Tablets of Revumenib Into Pediatric R/R Acute Leukemia Management

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss the use of 25-mg tablets of revumenib in pediatric KMT2A-translocated relapsed/refractory acute leukemia.

When to Test for KMT2A Rearrangements and Other Alterations in Pediatric Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss the optimal timing of testing for KMT2A rearrangements in pediatric acute leukemia.

Implications of the FDA Approval of Revumenib in KMT2A+ R/R Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, on the significance of the FDA approval of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.